To estimate the prevalence of insomnia and examine its correlates (for example, demographics and physical and mental health) and treatments.
I nsomnia is characterized by diffi culty initiating or maintaining sleep, or nonrestorative sleep, and is associated with impairments of daytime functioning. 1, 2 Insomnia may present as a symptom or a disorder on its own. It is the most prevalent sleep disorder and its course may be situational, recurrent, or persistent over time. 3 Epidemiologic studies have documented the prevalence of insomnia in several countries around the world but estimates derived from these studies have been extremely variable, with prevalence rates ranging from 5% to 50%. 4 Although this variability may be explained partly by cultural differences, it is most likely attributable to methodological differences across studies (for example, insomnia defi nitions and different sampling and assessment methods). Two Canadian surveys have also yielded variable prevalence rates of 13.4% 5 and 24%. 6 Both of these studies used a single question to assess the presence of insomnia (that is, diffi culties in initiating or maintaining sleep) but used different response formats, which may explain the 10% discrepancy. Indeed, the fi rst study (13.4%) used response choices assessing both the presence and frequency of the symptoms (that is, none of the time to all of the time), while the latter (24%) used a yes or no format, assessing only the presence of the symptom. Neither of these studies assessed the duration, severity, or impact of sleep diffi culties on the person's life, indicators that are all part of the standard diagnostic criteria for insomnia. 1, 2 Using a standard algorithm based on a combination of DSM-IV-TR 2 and ICD-10 7 diagnostic criteria for insomnia, our group sampled French-speaking adults in the province of Quebec and found that 29.9% reported insomnia symptoms and 9.5% met all criteria for an insomnia syndrome. 8 Among adults with an insomnia syndrome, 41.9% reported having used prescribed or over-the-counter medications for sleep in the preceding year. Our paper is based on a second survey conducted across Canada to expand on these early fi ndings. The main objectives were to estimate the prevalence of insomnia syndrome and symptoms and their correlates, and to evaluate the rate of health care consultations for sleep problems and the use of sleep-promoting products in Canada. Our study was part of a larger epidemiologic research program aimed at documenting the prevalence and incidence, risk factors, natural history, and burden of insomnia.
Method

Defi nition of Insomnia
An algorithm based on a combination of DSM-IV-TR 2 and ICD-10 7 insomnia diagnostic criteria was used to classify people with an insomnia syndrome or with symptoms. Criteria for an insomnia syndrome were: dissatisfaction with sleep; presence of symptoms of initial, middle, or late insomnia at least 3 nights per week for a minimum of 1 month; and signifi cant distress or daytime impairment related to sleep diffi culties. Initial insomnia was defi ned by sleep onset latency of greater than 30 minutes, middle insomnia was defi ned by a period of wakefulness after sleep onset lasting more than 30 minutes, and late insomnia was defi ned by a fi nal awakening occurring more than 30 minutes before the desired wake time combined with a total sleep time of less than 6.5 hours. People reporting insomnia symptoms or sleep dissatisfaction without meeting all criteria for an insomnia syndrome were classifi ed as having insomnia symptoms.
Sample Selection
The target population consisted of people aged 18 years or older residing in one of the main Canadian regions (that is, British Columbia, the Prairies, Ontario, the Maritimes, and Quebec). A random digit dialing method programmed to generate geographically stratifi ed phone numbers (listed and unlisted phone numbers) according to the last Canadian Census (2006) was used to obtain a representative sample of these 5 regions. The Kish method 9 was then used to identify the interviewee in each household. This method allows for the random selection of participants while taking into consideration the number of residents, their sex, and age. When there was no response in a household, the same phone number was dialed again up to 10 times at different times of the day before being replaced. People who declined to participate in the survey on fi rst contact were called a second time before exclusion.
People were excluded if they did not speak English or French well enough to complete the interview, or suffered from any condition (for example, hearing or cognitive impairment) that might prevent them from completing a telephone interview. Among the 4869 productive phone numbers dialed, 2000 (41%) people accepted to complete the interview. Among those, 1068 were French speaking and 933 were English speaking. Participants were distributed as follows across the main Canadian regions: British Columbia (n = 200), Prairies (n = 200), Ontario (n = 200), Maritimes (n = 200), and Quebec (n = 1200). The province of Quebec was oversampled for the purpose of another study that involved an overnight evaluation of sleep.
Interview
Interviews were conducted in French or English by a professional poll company. Interviewers received training and a pilot test was conducted on 44 people (not included in the fi nal sample) to improve the items wording and provide After obtaining verbal consent, the interviewer proceeded to ask questions about sleep schedules and diffi culties, consultations for sleep problems, and the use of products to promote sleep, physical and mental health status, and demographics.
Sleep and Insomnia. The fi rst part of the interview covered sleep diffi culties in the preceding month, including type of insomnia symptoms, their severity, duration, and impact. Standard questions from the ISI were asked. 10 Respondents rated the severity of their diffi culty falling asleep, staying asleep, or waking up too early using a 5-point scale (that is, no diffi culty to very severe diffi culty). These questions were followed by estimates of weekly frequency of: sleep onset latency exceeding 30 minutes, time awake after sleep onset of greater than 30 minutes, fi nal morning awakening occurring at least 30 minutes before the planned time, and total sleep time of less than 6.5 hours. Participants rated their sleep quality using a 4-point scale (that is, very refreshing to not refreshing) and the weekly frequency of experiencing nonrefreshing sleep. Sleep satisfaction was then evaluated using a 5-point scale (that is, very satisfi ed to very dissatisfi ed). Finally, for people dissatisfi ed or very dissatisfi ed with their sleep, or those reporting sleep problems (yes or no question), the duration was recorded and the consequences (that is, impairment of daytime functioning, fatigue, and mood disturbance), noticeability to others, and the level of concern about the diffi culties were rated using a 5-point scale (that is, not at all to very much). Participants were also asked if a health care professional had ever diagnosed a sleep disorder other than insomnia (for example, sleep apnea or restless legs syndrome).
Consultations and Products Used for Sleep Problems.
Respondents were asked if they had ever consulted a health care provider specifi cally for sleep problems and, if so, the type of provider and if the consultation had occurred in the last year. They were asked if they had used any of the following products to promote sleep in the preceding year: prescription medications (for example, zopiclone), over-the-counter medications (for example, Nytol), natural products (for example, valerian), and alcohol. They were asked to estimate their weekly use during the preceding month.
Health. Respondents were asked to rate their physical and mental health on 5-point scales (that is, excellent to poor). They were also asked if they had experienced general health or psychological problems in the last month (yes or no). Symptoms of anxiety (that is, "In the last month, have you been worrying and feeling nervous most of the time in your daily life?") and depression (that is, "In the last month, did you go through a period of at least 2 weeks during which you felt depressed or lost interest in things most of the time?") were also assessed. The interview concluded with sociodemographic questions.
Data Analysis
Based on the 2006 national census, data were weighted by region and sex to adjust for the oversampling of respondents from the province of Quebec and to ensure adequate representation of different subgroups. Sample sizes reported in tables and fi gures refer to the actual number of respondents, and percentages refer to weighted data. Confi dence intervals (95%) were calculated for prevalence rates. Weighted chi-square tests were used to examine the associations between insomnia and demographic and clinical variables, and between insomnia prevalence, health care consultations, and the use of sleep aids, and the Canadian regions. Signifi cant chi-squares comparing the regions were followed by post hoc comparisons (critical P values adjusted using Bonferroni correction), comparing each region with the others in 2 × 2 contingency tables. 11, 12 Weighted univariate odds ratios were calculated to evaluate the risk of having an insomnia syndrome according to different demographic and clinical characteristics. T tests were computed to examine group differences on total sleep time and insomnia severity. Analyses were performed using SPSS version 13.0 (SPSS Inc, Chicago, IL) and SAS version 9.1 (SAS Institute, Cary, NC) and an alpha level of 5%.
Results
Sample
The 2000 participants were aged between 18 and 99 years (mean 48.6, SD 18.1). After weighting, the sample included 51% women and 49% men (compared with unweighted 60.5% and 39.5%, respectively). The majority of participants (92.9%) had completed at least a high school degree, were married or living with a partner (60.1%), working full time (64.3%), and lived in an urban area (42.8%) (demographics are presented in the sample description column of Table 1 ). Among all interviews, 53.4% were completed in French. Missing data were unrelated to sex but were related to age. Participants with missing data (n = 33; 1.7%) were signifi cantly older (58.7, compared with 48.9) than those without missing data; t = 2.76, df = 1998, P = 0.006. Table 1 presents prevalence rates of insomnia syndrome according to demographic variables. There were signifi cant differences in the proportion of people with an insomnia syndrome according to sex, age, marital status, education, and family income. Occupation and living area were not associated with prevalence. Odds ratios showed that women were 1.50 times more at risk (P = 0.02) to present an insomnia syndrome than men. Compared with the group aged 18 to 29 years, the groups aged 30 to 39 and 50 to 59 years were 1.65 and 1.66 times, respectively, more at risk of having insomnia (P < 0.01); the risk of older age groups was not signifi cantly different. Divorced, separated, and widowed respondents were more likely to report insomnia than singles (OR 1.81 and 1.99, P < 0.01, respectively), as were people with lower education (that is, elementary or less, OR 1.67; junior college degree, OR 1.86, P < 0.01), compared with respondents with a university degree. Table 3 presents insomnia syndrome prevalence rates according to physical and mental health variables. These rates were signifi cantly higher in people with poor selfrated physical health (35.6%) and among those reporting physical health problems in the month preceding the interview (26.5%). Likewise, people who rated their mental health as poor or who reported psychological problems in the prior month also presented higher prevalence rates (41.4% and 40.2%, respectively). People who reported anxiety symptoms in the previous month were also more likely to have insomnia (31.8%, compared with 7.6%), but there was no signifi cant difference for people with depressive symptoms, compared with those without (15.2%, compared with 24.2%). Finally, odds ratios ranged from 1.68 (depressive symptoms in the last month) to 6.45 (poor self-rated mental health), with higher risks for people reporting physical or mental health problems, compared with those without (with the exception of depressive symptoms).
Prevalence of Insomnia
Demographic and Clinical Correlates
Consultations for Sleep Problems
Thirteen per cent (95% CI 11.7% to 14.7%) of all respondents reported having consulted a health care provider for sleep problems at least once in their lifetime, including 55.5% who had consulted in the year preceding the interview. The most frequently consulted health care provider was a family physician (74.1%), followed by a psychiatrist (14.2%). Among participants with an insomnia syndrome, 37% reported at least 1 lifetime consultation, with 23.9% having consulted in the year preceding the interview.
Demographic and clinical variables signifi cantly associated with consultation were the same as those associated with insomnia (that is, sex, age, occupation, marital status, and physical and mental health), with the exception of education and income, which were not associated with consultation. n refers to actual number of respondents and % and 95% CI refer to weighted data.
Figure 1 Insomnia prevalence in the adult Canadian population
People who had consulted a health care provider presented more severe insomnia (mean ISI score 15.2, SD 3.2) than those who had not (mean ISI score 12.90, SD 3.7), t = 4.9, df = 248, P < 0.01.
Medications and Products Used to Promote Sleep
In the year preceding the survey, 10% (95% CI 8.7% to 11.3%) of the sample had used prescribed medications for sleep, 9.0% (95% CI 7.8% to 10.3%) had used natural products, 5.7% (95% CI 4.7% to 6.7%) had used over-thecounter medications, and 4.6% (95% CI 3.7% to 5.5%) had used alcohol. People using prescribed medications (59.2%) and natural products (51.7%) used them regularly (that is, 3 nights or more per week), while people using over-the-counter medication (22.2%) and alcohol (16.7%) reported regular use. Variables associated with regular use of prescribed medication were sex (that is, women;  2 = 5.37, df = 1, P < 0.05, n = 232), education (that is, primary;  2 = 12.76, df = 3, P < 0.01, n = 232), poor physical health ( 2 = 4.73, df = 1, P < 0.05, n = 232), and older age (t = 6.17, df = 259, P = 0.001). Perceived psychological status was not associated with regular use of prescribed medication and none of the demographic or clinical variables were associated with over-the-counter medication or natural products.
Comparisons Across Canadian Regions
There were signifi cant differences across regions regarding the proportion of people with insomnia symptoms ( 2 = 14.52, df = 4, P < 0.01, n = 1983) and syndrome ( 2 = 10.51, df = 4, P < 0.03, n = 1966) ( Table 4 ). Post hoc comparisons showed lower proportions of people with insomnia symptoms and syndrome in Quebec, compared with Ontario and the Prairies. French-speaking respondents (pooled across all regions) presented lower prevalence rates than English-speaking respondents both for insomnia symptoms (34.5%, compared with 44.3%;  2 = 10.56, df = 2, P < 0.001, n = 1242) and syndrome (9.5%, compared with 14.3%;  2 = 6.43, df = 2, P < 0.01, n = 1224).
Rates of consultations for insomnia were lower in Quebec (9.1%) than in the Prairies (16.9%) ( 2 = 12.49, df = 4, P < 0.05, n = 1990). French-speaking people reported a lower rate of lifetime consultation than English-speaking people (8.7%, compared with 14.4%;  2 = 9.14, df = 1, P = 0.003, n = 1996), although this difference was no longer signifi cant when considering only people with an insomnia syndrome (26.3%, compared with 38.8%).
Signifi cantly fewer Ontario residents were using prescribed sleep medications (6.7%) relative to residents from Quebec (11.5%), the Prairies (12.8%), or British Columbia n refers to actual number of respondents and %, χ 2 , and 95% CI refer to weighted data. a Anxiety and depressive symptoms are not in mutually exclusive categories and respondents could report both symptoms.
(12.8%) ( 2 = 15.81, df = 4, P < 0.01, n = 1986). More residents from Quebec used natural products than from Ontario (13.0%, compared with 7.9%;  2 = 15.81, df = 4, P < 0.05, n = 1983), while more residents from the Prairies than Ontario used alcohol (7.4%, compared with 3.4%;  2 = 11.21, df = 4, P < 0.05, n = 1988). Use of over-thecounter medications did not differ across regions. There were fewer English-speaking relative to French-speaking people using prescribed medications (9.3%, compared with 12.9%;  2 = 4.7, df = 1, P = 0.03, n = 1987), and natural products (7.4%, compared with 15.6%;  2 = 26.2, df = 1, P < 0.001, n = 1984), but a higher proportion of Englishspeaking people using over-the-counter medications (6.2%, compared with 3.5%;  2 = 4.6, df = 1, P = 0.03, n = 1990). There were no differences regarding alcohol use.
Discussion
The fi ndings indicate that insomnia is a prevalent condition, age-and sex-related, and strongly associated with physical and mental health status. Prevalence rates in our study are slightly higher than those previously reported for the province of Quebec 8 but lower than those obtained throughout Canada 5, 6 or elsewhere in the world. 4, [13] [14] [15] The lower fi gures in our study are most likely due to the use of a more stringent case defi nition; nonetheless, insomnia remains a prevalent condition whether the defi nition is in terms of symptoms or disorder. Despite its high prevalence, few people seek treatment and, when treatment is initiated, it usually involves prescribed medications.
The association between insomnia and demographic variables (for example, sex, marital status, education, or income) is consistent with previous studies, 4, 8, 13, 14 with the exception that, in our study, insomnia was associated with middle-age rather than with older age. While older adults are more likely to experience insomnia symptoms, they may be less likely to perceive and report such symptoms as problematic (that is, distressing and interfering with daytime functioning), possibly because of an adjustment during the chronic course of their sleep problem. Insomnia was strongly associated with physical and mental health, with people reporting poorer health being more likely to present an insomnia syndrome. For example, people reporting psychological problems in previous months were 5 times more likely to also experience insomnia, compared with those without such problems. These fi ndings, along with the observation that mixed insomnia is the most prevalent subtype of insomnia, are consistent with previous studies [16] [17] [18] [19] [20] [21] and suggest a high rate of comorbid psychiatric and medical disorders among people with insomnia.
Only 13% of the sample (37% of people with an insomnia syndrome) had consulted a health care provider specifi cally for sleep. With increasing evidence documenting the burden of chronic insomnia, [20] [21] [22] [23] [24] it is surprising that consultation rates remain so low. Limited knowledge about other therapeutic options other than medications for insomnia and the lack of providers with adequate training to treat this condition with nonpharmacological methods might partially explain why so few people seek treatment. Given that consultation was associated with insomnia severity, people with insomnia may delay seeking treatment until their sleep disturbance has reached a more severe and persistent course.
Despite low consultation rates, 10% of the sample had used a prescribed sleep medication in the preceding year, 9% had used a natural product, and 6% had used an overthe-counter product as a sleep aid. These fi gures suggest that many people may resort to self-help strategies in the absence of professional health care consultations, a practice that is not ideal considering the unknown risks and benefi ts of products that are not regulated by government health agencies. 25 Regional and language differences were observed regarding consultations and use of sleep-promoting products.
Residents from Quebec and French-speaking people across Canada reported lower rates of consultations than residents from other provinces and English-speaking people; paradoxically, a higher proportion of French-speaking people reported having used natural products for sleep. These differences may refl ect different cultural perspectives on the management of sleep diffi culties. Cultural differences in sleep patterns in ethnic and (or) minority groups have been observed in previous studies. 18 It is possible that both sleep patterns and treatment strategies for insomnia are infl uenced more by culture (refl ected by spoken language) than by regional living area (rural, compared with urban), or economic status, per se, although these may also refl ect different lifestyles. Future studies are needed to better understand the infl uence of culture on sleep patterns and treatment seeking.
It is also interesting to note that rates of sleep aid use reported in Canada were similar to those reported in France [26] [27] [28] and Norway, 29 and lower than in the United Kingdom 28, 30 and Germany. 28 Whether these differences are a function of cultural differences, different health care systems, or other factors remains unclear. In our study, however, there was no signifi cant relation between consultation and either education or income.
Two methodological issues may limit the interpretation of the fi ndings. First, the lack of a more detailed interview precludes establishing a clear relation between insomnia and comorbid medical and psychiatric disorders. Second, it is plausible that prevalence estimates, as in most insomnia surveys, were infl ated by people with other undiagnosed sleep disorders (for example, sleep apnea) that might present as insomnia. In the absence of polysomnographic recordings or a clinical interview to rule out these disorders, current estimates of insomnia most likely include people with other sleep disorders.
Our results further document the widespread prevalence of insomnia in the general population. These fi ndings highlight the need to develop effi cient public education programs to raise public awareness and formal training programs for health care practitioners to improve diagnosis and treatment of insomnia.
